Progyny, Inc. (PGNY)
NASDAQ: PGNY · Real-Time Price · USD
14.34
+0.15 (1.06%)
At close: Dec 20, 2024, 4:00 PM
14.33
-0.01 (-0.07%)
After-hours: Dec 20, 2024, 6:29 PM EST

Company Description

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States.

Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment.

In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services.

The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

Progyny, Inc.
Progyny logo
Country United States
Founded 2008
IPO Date Oct 25, 2019
Industry Health Information Services
Sector Healthcare
Employees 566
CEO Peter Anevski

Contact Details

Address:
1359 Broadway
New York, New York 10018
United States
Phone 212 888 3124
Website progyny.com

Stock Details

Ticker Symbol PGNY
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $13.00
CIK Code 0001551306
CUSIP Number 74340E103
ISIN Number US74340E1038
Employer ID 27-2220139
SIC Code 8090

Key Executives

Name Position
Peter Anevski CPA Chief Executive Officer and Director
David J. Schlanger J.D. Executive Chairman
Michael Sturmer President
Mark S. Livingston CPA Chief Financial Officer
Allison Swartz Executive Vice President, General Counsel and Secretary
Steven Leist Chief Technology Officer
James Hart Vice President of Investor Relations
Risa Fisher Chief Marketing Officer
Cassandra Pratt Chief Human Resources Officer
Julie Stadlbauer Chief Business Development Officer

Latest SEC Filings

Date Type Title
Dec 9, 2024 144 Filing
Dec 6, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 10-Q Quarterly Report
Nov 12, 2024 8-K Current Report
Nov 8, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 18, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Sep 18, 2024 8-K Current Report
Sep 5, 2024 UPLOAD Filing
Aug 15, 2024 UPLOAD Filing